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ABSTRACT
Background
HIV surveillance of generalised epidemics in Africa primarily relies on prevalence at antenatal
clinics, but estimates of incidence in the general population would be more useful. Repeated
cross-sectional measures of HIV prevalence are now becoming available for general
populations in many countries, and we aim to develop and validate methods that use these
data to estimate HIV incidence.
Methods and Findings
Two methods were developed that decompose observed changes in prevalence between
two serosurveys into the contributions of new infections and mortality. Method 1 uses cohort
mortality rates, and method 2 uses information on survival after infection. The performance of
these two methods was assessed using simulated data from a mathematical model and actual
data from three community-based cohort studies in Africa. Comparison with simulated data
indicated that these methods can accurately estimates incidence rates and changes in
incidence in a variety of epidemic conditions. Method 1 is simple to implement but relies on
locally appropriate mortality data, whilst method 2 can make use of the same survival
distribution in a wide range of scenarios. The estimates from both methods are within the 95%
confidence intervals of almost all actual measurements of HIV incidence in adults and young
people, and the patterns of incidence over age are correctly captured.
Conclusions
It is possible to estimate incidence from cross-sectional prevalence data with sufficient
accuracy to monitor the HIV epidemic. Although these methods will theoretically work in any
context, we have able to test them only in southern and eastern Africa, where HIV epidemics
are mature and generalised. The choice of method will depend on the local availability of HIV
mortality data.
The Editors’ Summary of this article follows the references.
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Monitoring the continuing spread of the HIV epidemic is
essential for determining public health priorities, assessing
the impact of interventions, and making estimates of current
and future health care needs [1]. Currently, surveillance
systems in generalized epidemics primarily rely on HIV
prevalence (fraction of population infected) data collected
from women attending selected antenatal clinics [2,3].
Interpretation of these data is complicated by natural
epidemiological changes that arise from the long and variable
incubation of HIV and AIDS-related mortality [4,5], by biases
in the sample due to subfertility associated with bacterial
sexually transmitted infections and HIV [6], and by the
disproportionate selection of surveillance sites in urban areas
[7]. Recently, serological testing has been included in house-
hold health surveys, such as the Demographic and Health
Surveys (DHS), giving estimates of HIV prevalence in the
general adult population based on a standard methodology
[8–10]. Measures that relate to the general population are
more useful, but there remain several important limitations in
using prevalence data to monitor the epidemic. These
limitations include the following. (i) Decreases in prevalence
do not necessarily indicate a reduction in risk of infection [5];
(ii) changes in prevalence lag behind real changes in risk,
particularly at older ages; (iii) comparisons of prevalence
between countries can be confounded by different survival
times following infection (e.g., if survival following infection is
shorter in Asia than in Europe or Africa [11–13], then similar
prevalence levels could mask higher incidence rates in Asia);
and (iv) the weak association between prevalent infection and
risk makes it difﬁcult to identify ‘‘high-risk’’ groups (e.g.,
higher average prevalence among women does not necessarily
mean they are at overall greater risk than men).
A better measure for monitoring the HIV epidemic is
incidence (rate of new infections among those at risk). If
incidence is known, temporal changes in the epidemic can be
betteridentiﬁedandcharacterised, thepatternofriskoverage
can be examined to aid the understanding of transmission
patterns and highlight targets for interventions, and future
health care needs can be predicted. However, whereas
prevalence can be measured with independent, anonymised,
cross-sectional serosurveys, direct measurement of incidence
would require individuals to be identiﬁed and followed up
from one serosurvey round to the next. In most settings,
achievinghighfollow-upratesisamajorlogisticalchallengeand
is more expensive than selecting a new panel of participants at
eachsurvey round.Newtypesof HIVtestthat candiscriminate
recent infections from a single specimen have not so far been
able to generate reliable estimates of incidence [14,15]. Most
household surveys do not follow up individuals, but it may still
be possible to estimate incidence from prevalence estimates in
successivesurveys,withoutusingcomplexprojectionpackages.
This paper describes and tests two methods for this form of
incidence estimation, with the intention that they can be
applied in future to sequential prevalence data collected in
household surveys, including the DHS.
Several methods have been proposed to estimate incidence
from measures of prevalence [16–25]. Some of these work
only in early epidemics [20], others only in stable conditions
[22]; some need long time-series [19–21] or involve compli-
cated and computationally intensive model-ﬁtting proce-
dures [16–25]. Most of the methods have not been validated
by comparing derived estimates with actual measurements,
and none to our knowledge has been validated with data from
more than one African community or in populations
experiencing mature or declining HIV epidemics. Further-
more, these earlier methods have not incorporated recent
ﬁndings on HIV mortality, and their performance has not
been assessed under evolving epidemiological conditions,
such as changes in risk and increasing access to antiretroviral
therapy (ART).
Both of our methods are simple to use and are based on the
idea of demographic accounting [22]. They examine the
change in HIV prevalence in a cohort observed at two time
periods, allowing for changes due to new infections and
mortality among infected and uninfected persons. To gather
the mortality data required to estimate incidence exactly
would also require cohort follow-up, but we show how
mortality information collected from external sources, such
as long-running cohort studies, can be used in place of direct
measurements. Method 1 uses cohort mortality rates among
those infected, whilst method 2 uses the distribution of
survival after HIV infection. We test the performance of these
methods using data generated by a mathematical simulation
model and actual measurements of prevalence and incidence
from three community-based cohort studies in Zimbabwe,
Uganda, and Tanzania.
Methods
Calculating Incidence from Cross-Sectional Prevalence
Consider cross-sectional measures of prevalence separated
by an interval of T years in age groups of width r years
(Figure 1A). Denote the total number of individuals in age-
group i at time j as Ni,j and the number of HIV-infected
individuals as Hi,j. Prevalence is deﬁned as pi;j ¼ Hi;j=Ni;j.W e
construct age cohorts centred on initial ages ai and size r
years, i.e., aged ai   r
2 to ai   r
2 at the start of each interval,
and ai   r
2 þ T to ai   r
2 þ T at the end. We denote the age
cohort experience of incidence as ~ ki (the diagonal parallelo-
gram in Figure 1A). By ‘‘age cohort’’ we refer to the
individuals in a particular age group at a particular time.
The conventional age-speciﬁc incidence rate for ages
ai   r
2 to ai   r
2 is deﬁned as (shown as a rectangular area in
Figure 1B). We note that ~ ki and ki are not t ki he
instantaneous rate of new infections but the average hazard
of new infections occurring in the interval. Over short
intervals with typical HIV incidence rates, these two ways of
describing incidence are very similar. In addition, we deﬁne
~ pi as the fraction of infected individuals in the i
th age group
at the start of the interval who survive to the second
serosurvey.
In a real cohort, we can ﬁnd an approximation to incidence
by considering the change in the number of HIV-infected
individuals and ﬁnding an approximation to the person-years
spent at risk of infection (PYAR) in the cohort [24].
Number of seroconversions
’Hi;T   ~ piHi;0 ð1Þ
Number of person-years spent at risk
’T
ðNi;0   Hi;0Þþð Ni;T   Hi;TÞ
2
  
ð2Þ
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Estimating Incidence from PrevalenceIt follows (details in Text S1) that an estimate of cohort
incidence in the interval is:
~ ki ’
2ðQipi;T   ~ pipi;0Þ
Tð1   pi;0 þ Qið1   pi;TÞÞ
Qi ’1  ð 1   ~ piÞpi;0  ð 1   expð ~ liTÞÞð1   pi;0Þ
ð3Þ
where Qi approximates the proportionate change in size of
the cohort over the time interval T and incorporates the
cohort mortality rate for those not infected (~ li). In practice, if
this expression gives a negative value for any ~ ki, it is replaced
with zero.
To estimate incidence in the cohort that is not included in
the data at the start of the time interval (but enters the
youngest cross-sectional age group during the interval), we
assume that incidence is zero at all ages younger than the
youngest person in the dataset (i.e., younger than a1   r
2). If
incidence is further assumed to be constant over the interval
and mortality is negligibly small at this age, we can describe
prevalence in this unseen cohort as: p0;T ¼ 1   expð T~ k0=2Þ,
where p0,T is the prevalence in the second serosurvey in the
age range a1   r
2 to a1   r
2 þ T, since the average exposure
time in that group is T
2. From this, we can generate an
estimate of incidence:
~ k0 ¼
 lnð1   p0;TÞ
T=2
ð4Þ
Method 1
Method 1 makes use of empirical values of age-speciﬁc
cohort mortality rates among those infected, which we denote
~ mi (Figure 1A). In this way, ~ pi can be approximated by
~ pi ¼ expð ~ miTÞ. Three sets of values for ~ mi are given in Table
1 that are appropriate for applications in early epidemics
(deﬁned as epidemics that are still expanding), mature stable
epidemics (epidemics that have stopped expanding), or
mature declining epidemics (epidemics that are in decline)
[26].
Method 2
Alternatively, if cohort mortality rates are not available, ~ pi
can be estimated using survival after infection information
[22] and an approximation of the current incidence pattern.
If we deﬁne s(a,z) to be the probability of survival to age z
given infection at exact age a and assume that the pattern of
incidence (relative levels of incidence at different ages) has
remained constant for as long as the oldest person in the data
has been at risk of infection, then provided T ’ r:
~ p1 ’
sa 1  
r
2
;a1 þ T
  
sa 1  
r
2
;a1
  
~ p1 ’
sa 1  
r
2
;a1 þ T
  
~ k0 þ
X i 1
k¼1
wksa k þ
r
2
;a1 þ T
     
sa 1  
r
2
;a1
  
~ k0 þ
X i 1
k¼1
wksa k þ
r
2
;a1
      for i.1
wk ¼ ~ kkexp  
X k 1
q¼0
~ kq
 !
ð5Þ
This expression calculates the chance that infected
individuals die during the follow-up period by assuming that
the composition of the infected populations in each age
group reﬂects the pattern of incidence at younger ages
(Figure 2). The numerator represents weighted survival from
infection at earlier ages to the midpoint of the i
th age group at
the end of the time interval [0,T]. The denominator is the
weighted survival to the beginning of the interval. Thus, the
ratio is the chance of survival from the start to the end of the
intersurvey period for individuals at the central cohort age.
We approximate the survival of those infected in each age-
group by assuming that they were all infected at the midpoint
of that age group and this approximation will be more
accurate for smaller values of r. The weights (wk) are derived
from calculating the chance that an individual was infected at
each age group, which is the product of incidence in each age
group and the probability that they were not infected at
younger ages. For simplicity, we do not represent the periods
for which individuals were exposed to these rates, but since
the same terms are used in the numerator and denominator
of Equation 5 this does not have an important effect provided
r and T are small.
Since values of ~ pi are calculated using estimates of
incidence from younger age groups, which themselves
depend on ~ pi, the order of calculation matters; it should be
~ k0;~ p1;~ k1;~ p2;~ k2, and so on. These expressions can be
evaluated in full automatically using standard spreadsheet
software (Text S2).
The probability of survival for z years after infection at age
a is modelled as a Weibull distribution:
sða;zÞ¼exp  ½ z=ba f  
kg
  
ð6Þ
where k and ba are the shape and scale parameters,
respectively. The scale parameter (but not the shape
parameter) is assumed to depend on the age at infection.
Suggested values of the parameters are given in Table 2,
which are from a recent meta-analysis of survival rates in
southern and eastern Africa [27].
An alternative formula can be used if T , r (see Text S1).
Methods 1 and 2: Derivation of Cross-Sectional Measures
The ﬁnal step in calculating incidence by methods 1 and 2
is to convert the cohort incidence rates into incidence rates
that relate to conventional cross-sectional age groups (Figure
1B and 1C). If we assume that the cohort seroconversion rates
apply uniformly in the follow-up period, we can do this
conversion using:
ki ¼ 1  
T
2r
  
~ ki þ
T
2r
  
~ ki 1 ð7Þ
The estimate pertains to the interval between two
serosurveys and relies on the intersurvey interval being no
greater that the width of the age groups (T   r). If T . r then
the same logic holds, but, because more cohorts pass through
the cross-sectional age groups in the period T, an alternative
to Equation 7 for the relative weights of the cohorts is needed
(see Text S1).
Both methods assume that the true rate of incidence in the
population is low, that incidence has remained stable in the
interval between the two surveys, and that the width of the
age groups and the interval between the surveys is short. Even
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incidence rates are typically less than ;4% [1,28], and in
household health serosurveys such as DHS, the width of age
groups and the interval between surveys is usually 5 y. We
therefore believe that these methods are adequate to
estimate HIV incidence in most settings with such data.
Method 1 further assumes that the pattern of incidence in
the populations from which the mortality data are taken is
similar to that of the target population. Method 2 instead
further assumes that the age pattern of incidence has
remained constant for several years and that survival rates
with HIV for those infected while in the same age group are
approximately equal. The performance of the methods when
these assumptions are violated has been assessed by applying
the methods to simulated data (see Text S1 for details of
simulation model).
Validating the Methods in Community-Based Cohort
Studies in Africa
To test how well these methods perform, we compare
incidence estimates derived using these two methods with
actual measurements made in cohort studies. Data were used
from three community cohort studies in sub-Saharan Africa;
the Manicaland HIV/STD Prevention Project in Zimbabwe
[29], the MRC/UVRI Uganda Research Unit on AIDS, which
runs a cohort in Masaka district [30] and the NIMR TAZAMA
cohort study in Kisesa ward, Tanzania [31]. The Manicaland
study furnishes suitable data for only one test time interval
(two serosurveys 3 y apart); the Kisesa study provides three
test intervals (four surveys, each separated by about 3 y). The
Masaka study has conducted 17 annual serosurveys, but 1-y
intervals do not generate sufﬁcient incident cases for robust
age-speciﬁc incidence estimates. To overcome this problem,
longitudinal knowledge of HIV status was used to establish
HIV prevalence measures at four points in time giving three
test intervals in which to measure prevalence, separated by
roughly 4 y.
For validation, we used data from ‘‘closed cohorts’’; that is,
we did not include individuals who entered the cohort
during a particular interval or were not seen at follow-up and
were not known to have died. Seroconversion dates were
assigned between the last negative and ﬁrst positive test
results in accordance with analysis procedures developed at
each site [32–35]. Poisson-based conﬁdence intervals were
calculated for each incidence measurement, which do not
take account of any clustering effects in the samples. For
method 1, cohort mortality rates typical of ‘‘mature,
Figure 1. Lexis Diagrams Showing Values Used in the Methods
Two serosurveys T years apart quantify prevalence in age groups of width r. One age group (i) is shown.
(A) At time j,N i,j is the total number in survey; Hi,j is the number infected; pi,j is HIV; ~ pi is the fraction of infected individuals that survive between surveys;
~ miis mortality rate of infected individuals in the cohort; ~ ki is the rate of HIV incidence in the cohort. N and H are not used required to use the methods
but do appear in the mathematical derivation.
(B) Cross-sectional incidence (~ ki).
(C) Contributions to cross-sectional incidence estimate from incidence in two cohorts (~ ki and ~ ki 1). For details see main text and Text S1.
doi:10.1371/journal.pmed.0050080.g001
Table 1. Cohort Mortality Rates for HIV-Infected Persons,
Tabulated by Age of Cohort at Start of Five-Year Interval and
Epidemic Phase [26]
Age Group, Years Early Mature, Stable Mature, Declining
15–19 0.017 0.028 0.044
20–24 0.023 0.037 0.060
25–29 0.029 0.048 0.077
30–34 0.036 0.059 0.095
35–39 0.043 0.070 0.114
40–44 0.051 0.083 0.134
45–49 0.058 0.095 0.154
50–54 0.066 0.109 0.175
55–59 0.075 0.122 0.197
60–64 0.083 0.136 0.220
Cohort mortality rates typical of mature, declining epidemics were used for Manicaland
and Masaka, and rates typical of mature, stable epidemics were used for Kisesa.
doi:10.1371/journal.pmed.0050080.t001
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and rates typical of ‘‘mature, stable’’ epidemics were used in
Kisesa (Table 1) [26].
Results
Testing the Methods on Simulated Data
Simulating data and comparing the known incidence rates
with estimates using these methods conﬁrm that incidence
can be accurately estimated from serial measures of cross-
sectional prevalence. Both methods slightly underestimate
incidence when the rate is high and in younger age groups,
because infections occur rapidly, and the person-years spent
at risk are overestimated by the linear assumptions that
underlie the approximations. Although the methods assume
that incidence is constant in the period between serosurveys,
accurate estimates of average incidence can be obtained for
this period even if incidence is increasing or decreasing
(Figure 3A and 3B). When incidence falls suddenly, estimates
of incidence are immediately reduced and continue to
estimate incidence accurately (Figure 3C). In these circum-
stances, measures of prevalence are slower to respond; after a
dramatic fall in incidence of 50% over 5 y, prevalence is
expected to decline by only 14%, whereas estimates of
incidence based on these methods indicate a 22% reduction
(the true average reduction in the 5 y interval is 25%).
Immediately after a sudden change in incidence, the
estimates are slightly too low because mortality in the older
age groups is transiently higher than it would be in a long-
term equilibrium with the new pattern of incidence. This bias
is smaller when the reduction in incidence is more gradual or
when incidence is lower in older age groups.
The methods for estimating incidence depend on using
mortality information from an external source. A potential
difﬁculty is that the pattern of mortality actually depends on
the pattern of incidence, which is determined by many
behavioural factors and could vary between populations and
over time. Simulating two alternative scenarios, in which
incidence is either highest at young ages (typical for women)
or highest at middle ages (typical for men), we can compare
the attendant patterns of mortality (Figure 4A). For both
scenarios, mortality is low at young ages but much higher at
older ages if incidence peaks at young ages. Estimating
incidence using method 1 requires age-speciﬁc mortality
rates for infected individuals and, if the rates used accurately
reﬂect the pattern of mortality in the population, the
estimates will be good (solid lines, Figure 4B). However, if
the mortality rates are taken from a population with a
different distribution of incidence and mortality, the derived
incidence estimates will be biased, particularly at older ages
(dashed lines, Figure 4B). This bias is small if incidence is
concentrated at young ages. Method 2, which does not rely on
using age-speciﬁc mortality rates, is able to accurately predict
incidence in either scenario using the same data on survival
after infection and assuming that age patterns of incidence
have remained constant in the years preceding the surveys.
When the age pattern of incidence changes over time, small
errors are introduced to the estimates using method 2 (Figure
4C). The errors are highest when the change occurs shortly
before the ﬁrst survey or in the interval between the two
surveys.
If ART provision increases from 0% to 30% in the interval
between two serosurveys, then the derived estimates of
incidence are too high when mortality data from the pre-
ART era are used (Figure 5). (ART coverage levels are likely to
be much lower than this in most countries in sub-Saharan
Africa [36].) This overestimate occurs because individuals are
surviving longer with infection leading to increased HIV
prevalence, but that prevalence trend is wrongly attributed to
new infections by the estimation methods. In these simu-
lations, incidence among adults is only slightly overestimated
at ﬁrst (;4%), and the errors are mostly limited to older ages.
The errors in later estimates of incidence, based on
Table 2. Parametric Model Estimates of Survival after Infection in
Southern and Eastern Africa
Age Group Weibull Survival Distribution Parameters
Shape Scale Median
15–19 2.0 16.0 13.3
20–24 2.0 15.4 12.8
25–29 2.0 14.1 11.7
30–34 2.0 12.1 10.0
35–39 2.0 11.0 9.1
40–44 2.0 10.1 8.4
45–49 2.0 7.9 6.6
These values are model fits to previously published data [27].
doi:10.1371/journal.pmed.0050080.t002
Figure 2. Lexis Diagram Showing How Cohort Mortality Rates Can Be
Estimated Using Data on Survival after Infection
In order to estimate expected mortality in one cohort (here ~ m3) using
data on survival after infection, it is necessary to approximate the
composition of the infected population in that cohort with respect to
time since infection. Thus, it is necessary to consider the previous
exposure of that cohort to incidence (indicated by the grey lines and
text). When the intersurvey period is the same as the width of the age
groups (T ¼ r), and the pattern of incidence is constant, the previous
experience of the cohorts will be reflected in the experience of younger
cohorts (i.e., cohorts 0, 1, and 2).
doi:10.1371/journal.pmed.0050080.g002
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greater as more individuals start ART. Errors at younger ages
also increase over time, particularly if incidence is high at
young ages.
Testing the Methods on Data from Cohort Studies
Measurements of incidence in adult and young people,
together with the corresponding estimates from both
methods are given in Table 3. Almost all estimates fall within
the 95% conﬁdence interval of the observed measurements.
For method 1, the mean difference between the measure-
ments and estimates for adults is 19%. For method 2, the
mean difference is 14% and it is less than 10% in half of the
comparisons. Neither method tends to systematically over- or
underestimate incidence.
Measured and estimated incidence rates are compared by
age group in Figure 6. The overall performance of both
methods is good; the pattern and approximate level of
incidence is captured successfully in all cases. The estimates
lie within the 95% conﬁdence interval of measurements in
80% (method 1) and 88% (method 2) of comparisons. The
average error across all comparisons at each age group for
each pair of surveys and at each site is ;35% for both
methods. Estimates at older ages are most likely to deviate
from measurements substantially. The estimates of incidence
among 25- to 34-y-old men and women in the ﬁrst period in
Masaka are the least accurate (Figure 6B).
Discussion
We developed two methods for estimating HIV incidence
in the general population using successive rounds of cross-
sectional prevalence data, and tested how well these methods
perform using model-simulated data and real data from three
African cohort studies. Spreadsheets for implementation of
both methods to estimate incidence are provided in Text S2.
Both methods provided good estimates of incidence in adults
and young people and captured the pattern of incidence with
Figure 3. Comparison of True Simulated Incidence Rate (Grey Lines) and Estimates Using Either Method (Black Lines; Both Give Same Results) when
True Incidence Increases Steadily (A), Decreases Steadily (B), or Decreases Suddenly (C)
Vertical lines indicate when five-yearly serosurveys are done. Estimates of incidence are made at the time of the serosurvey (open circles) but relatet o
the preceding 5-y period.
doi:10.1371/journal.pmed.0050080.g003
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directly at large scales, these methods could be of substantial
use in monitoring and comparing the progress of national
epidemics, contributing to the interpretation of observed
behavioural or epidemiological trends, and reﬁning estimates
of disease burden, treatment needs, and the future course of
the epidemic. The serial measurements of cross-sectional
prevalence that are required for these methods will soon be
available from household surveys with HIV testing, such as
DHS.
Estimates of incidence in adults and young people were in
very close agreement with actual measurements. Greater
discrepancies occurred at older ages, because these estimates
are most sensitive to the assumptions about mortality and
because the comparison incidence measurement itself is
more uncertain due to relatively small numbers of serocon-
versions. Both methods markedly underestimate incidence in
the ﬁrst period from Masaka among 25- to 34-y-old men and
women. This underestimate could result from (i) rapid
changes in incidence and prevalence at this time (1991–
1995), when there was a transition from epidemic growth to
decline [35], or alternatively, (ii) the mortality rates used in
the calculations being too low because the underlying
stability assumptions of both methods were breached by
changes in the age pattern of incidence. Such changes are
now unlikely in most other African countries where
epidemics have matured gradually.
For method 2, the mean error in these estimates of
incidence in adults is low: 14% over all comparisons or
10% if the earliest data from Masaka are excluded. For
method 1 the mean error is slightly greater (19%), but the
mortality rates used were based on regional aggregated data
[26] and the accuracy of estimates would be higher if local
data were used instead. The uncertainty in estimates made in
other settings is hard to quantify and will extend beyond
random statistical errors, because the extent to which
assumptions and approximations hold will not be known.
However, some insight can be derived by using a range of
scenarios for the mortality data, which reﬂect a range of
epidemiological conditions (Table 1) [26].
Simulations indicate that these methods could be used to
identify and quantify changes in incidence earlier and more
accurately than when only trends in prevalence are examined.
This is an important application since the monitoring of
trends is essential for coordinating an effective response to
epidemics [37,38]. However, changes in incidence estimates
Figure 4. Comparison of Method Estimates With Simulated Data Under
Range of Conditions Violating Underlying Method Assumptions.
(A) The age-specific mortality rates for HIV-infected individuals when
incidence is highest at young ages (dark line with crosses) or middle ages
(grey line with triangles).
(B) Estimates of incidence using method 1 when the ‘‘wrong’’ pattern
age-specific mortality rates are used (i.e., from the alternative scenario in
[A]: dashed lines) and when the correct rates or method 2 is used (solid
lines). Bars show simulated incidence rates.
(C) Estimates of incidence using method 2 when the age pattern of
incidence changes (instantaneously between the two scenarios shown in
[B]), 5 y (thick line), 10 y (dash-dot line), or 15 y (thin line) before the first
survey. The dotted lines show the estimate if the age pattern of
incidence does not change; the line with circles shows the estimates if
the age pattern changes in the interval between the two surveys. The
bars show the average incidence rate in the intersurvey period.
doi:10.1371/journal.pmed.0050080.g004
Figure 5. Incidence Estimates Using Method 2 Assuming that Provision
of Antiretroviral Therapy is Scaled Up from 0% to 30% over Five Years
The grey line with circles shows the estimate of incidence based on
surveys before and after the 5-y scale-up; the grey line with triangles
shows the estimate of incidence based on surveys after scale-up, while
provision is maintained at 30%. The black line shows the estimates if ART
is not provided. Graphs show the simulations assuming that the
incidence rate is highest at (A) older ages and (B) young ages. Similar
results are obtained using method 1.
doi:10.1371/journal.pmed.0050080.g005
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so data from parallel behavioural surveillance must be used to
assess this possibility when such changes are found [37].
In principle, these methods should work just as well in
other settings, provided that locally applicable mortality data
are used. The data we have used in the validation exercise
were considered appropriate because they came from the
same region and from a period during which ART was not
widely available. The choice of method (1 or 2) elsewhere will
depend on which assumptions seem more likely to be true for
the population in question and on the availability of locally
collected data. The investigations using simulated data alert
us to the danger of using the wrong age-speciﬁc mortality
rates in method 1, which can vary according to the phase of
the epidemic and the prevailing pattern of incidence. We are
reassured that in some settings the age-speciﬁc mortality
rates follow a similar pattern [26], but this does not
necessarily mean that they will do so elsewhere [39] (e.g., in
other types of communities or other parts of Africa). Method
2, on the other hand, may be applied to settings with different
incidence patterns using the same data on survival after
infection, because it effectively calculates its own mortality
rates by assuming that incidence patterns have remained
constant in the recent past. The agreement between the
results from the two methods indicates how successfully the
procedure for estimating mortality rates in method 2 works.
Applying cohort mortality rates or data on survival post-
infection from populations without treatment to populations
in which treatment has been available for several years could
lead to inﬂated estimates of incidence. We recommend that
method 1 be used where recent age-speciﬁc cohort mortality
data that pertain to the population in question are available;
but where they are not, method 2 may be used with a regional
estimate of survival after infection instead.
In the tests against actual measurement of incidence, the
mortality rates used were partly informed by data from the
same cohorts (50% of the person-years used to derive the age-
speciﬁc estimates in [26]). This may overstate how well
method 1 will perform at a national level, because there
would not necessarily be such agreement between the actual
mortality in the population in question and in the external
mortality rates that are used. We emphasise that in this study
we sought to validate the methods rather than a particular set
of mortality data. Also, whilst in these tests we have been able
to use real cohorts to measure incidence, in the application to
the household surveys with HIV testing, cross-sectional
prevalence measures for birth cohorts (with different
individuals appearing in the two serosurveys) would have to
be relied upon. As with other analyses of trends in prevalence,
as long as any differences in participation rate according to
serostatus remain constant, no additional biases will be
introduced.
Table 3. Measurements and Estimates of Incidence in Adults
Population Location
and Period
Sex Age Group,
Years
Incidence,
Observed
95% CI Estimated
Incidence,
Method 1
Agreement Estimated
Incidence,
Method 2
Agreement
Adults Manicaland 1 Male 15–54 1.76 1.43–2.16 2.04 ** 1.74 ***
Manicaland 1 Female 15–54 1.48 1.23–1.79 2.07 — 1.78 *
Masaka 1 Male 15–44 0.44 0.29–0.67 0.28 — 0.28 —
Masaka 1 Female 15–44 0.61 0.43–0.86 0.41 — 0.38 —
Masaka 2 Male 15–44 0.63 0.43–0.91 0.60 *** 0.52 **
Masaka 2 Female 15–44 0.37 0.23–0.61 0.42 ** 0.40 ***
Masaka 3 Male 15–44 0.40 0.28–0.57 0.48 * 0.42 ***
Masaka 3 Female 15–44 0.57 0.43–0.75 0.56 *** 0.53 ***
Kisesa 1 Male 15–44 0.74 0.51–1.09 0.72 *** 0.74 ***
Kisesa 1 Female 15–44 0.87 0.63–1.21 0.76 ** 0.81 ***
Kisesa 2 Male 15–44 1.42 1.09–1.84 1.13 * 1.17 **
Kisesa 2 Female 15–44 1.32 1.03–1.67 1.00 * 1.08 **
Kisesa 3 Male 15–54 1.21 0.93–1.58 0.89 * 1.05 **
Kisesa 3 Female 15–54 1.19 0.94–1.49 0.95 ** 1.11 ***
Young people Manicaland 1 Male 17–25 1.24 0.59–2.61 1.63 — 1.63 —
Manicaland 1 Female 15–25 2.00 1.33–3.01 2.22 ** 2.22 **
Masaka 1 Male 15–24 0.31 0.16–0.62 0.38 * 0.34 ***
Masaka 1 Female 15–24 0.98 0.64–1.50 0.91 *** 0.80 **
Masaka 2 Male 15–24 0.29 0.14–0.61 0.41 — 0.39 —
Masaka 2 Female 15–24 0.52 0.28–0.97 0.61 ** 0.52 ***
Masaka 3 Male 15–24 0.27 0.15–0.50 0.43 — 0.41 —
Masaka 3 Female 15–24 0.73 0.50–1.07 0.87 ** 0.80 ***
Kisesa 1 Male 15–24 0.39 0.10–1.56 0.45 ** 0.44 **
Kisesa 1 Female 15–24 1.09 0.45–2.61 1.04 *** 1.02 ***
Kisesa 2 Male 15–24 1.42 0.68–2.98 1.47 *** 1.47 ***
Kisesa 2 Female 15–24 1.93 1.17–3.21 1.49 * 1.48 *
Kisesa 3 Male 15–24 1.15 0.37–3.57 1.13 *** 1.13 ***
Kisesa 3 Female 15–24 1.25 0.56–2.79 0.94 * 0.93 *
All incidence values given per 100 pyar. Estimated value are standardised to same age-distribution as measurement.
Agreement between estimate and measurement: absolute error values *** , 10%; ** , 20%; * , 30%.
CI, confidence interval.
doi:10.1371/journal.pmed.0050080.t003
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Estimating Incidence from PrevalenceFigure 6. Result from the Cohort Studies Analysis
For each graph, the bars show incidence measured in the closed cohort with 95% confidence intervals and the lines show derived incidence estimates
using method 1 (dark grey line) and method 2 (light grey line). (A) Manicaland; (B) Masaka, period 1; (C) Masaka, period 2; (D) Masaka, period 3; (E)
Kisesa, period 1; (F) Kisesa, period 2; (G) Kisesa, period 3.
doi:10.1371/journal.pmed.0050080.g006
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Estimating Incidence from PrevalenceThe methods do not correct for differential migration
between infected and uninfected individuals and, by using
closed populations, we have removed the effect of migration
from the test data, which may improve their performance.
However, we intend these methods to be applied to national-
level data, and since rates of international migration are
much lower than internal migration (e.g., between rural and
urban areas and migration in and out of ﬁeld sites in cohort
studies), international migration should not introduce serious
errors. Moreover, incidence estimates will only be misleading
if migration rates vary by HIV status; for example, incidence
will be underestimated if infected individuals are more likely
to leave the country than others, or overestimated if
individuals from a higher-prevalence country immigrate.
Although regional migration has been associated with HIV
infection in spreading epidemics [40], it is thought that this
pattern is mostly driven by increased vulnerability to
infection rather than more frequent movement among
high-risk groups [41,42]. Most cross-sectional studies cannot
distinguish these possibilities, but recent cohort data from
eastern Zimbabwe show that rural–urban migrants currently
have socioeconomic characteristics and vulnerability to HIV
before migrating similar to those of nonmigrants [43]. In
most settings it is not possible to quantify rates of migration
with respect to HIV status, but if the same association is true
for international migrants it is unlikely that migration will
lead to large errors in incidence estimates. Therefore, as with
other analyses of prevalence time series [7], the estimates
should be interpreted with care if international migration
rates are high, have recently changed, or are dominated by
movement from a country with a very different HIV
prevalence.
If treatment with ART becomes more common, the
mortality rate of infected people will change, and use of the
mortality data provided here would lead to overestimates of
incidence, particularly at older ages, for which the effect of
ART will be greatest. However, our simulations indicate that,
in the next few years, this error may be small because not all
of those in need will start treatment [36], and the proportion
of infected individuals who are on treatment will increase
gradually over time. If survival on ART is longer than we have
assumed, then we would expect the errors to be greater. The
errors in the estimates would increase over time if mortality
data from the pre-ART era continued to be used, but new
data from cohort studies incorporating the impact of ART
will soon become available. The utility of these new measure-
ments will depend on the criteria for treatment access and
uptake levels being broadly similar in the cohort studies and
national populations. Estimates of incidence among young
people (under age 25 y) using existing mortality data from the
pre-ART era are expected to remain reliable even when ART
is common, as we have found that HIV mortality and ART
eligibility are very low in this age range [44].
Supporting Information
Text S1. Derivation of Methods and Further Technical Information
Found at doi:10.1371/journal.pmed.0050080.sd001 (89 KB PDF).
Text S2. Spreadsheets for Implementation of Methods 1 and 2 to
Estimate Incidence
Found at doi:10.1371/journal.pmed.0050080.sd002 (116 KB XLS).
Acknowledgments
The cohort data used for this work were put together in a series of
workshops organised by the ALPHA Network, funded by the
Wellcome Trust.
Author contributions. The study was jointly conceived and written
by all authors. TBH, BZ, SG, and JTB developed the methodology.
TBH, BZ, JT, BL, MW, and SB prepared and analysed data from the
cohort studies.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2006) 2006
Report on the global AIDS epidemic. Geneva: United Nations. Available:
http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp. Ac-
cessed 8 March 2008.
2. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance
(2000) Guidelines for second generation HIV surveillance for HIV: The
next decade (2000). Geneva: WHO. WHO/CDS/EDC/2000.05. Available:
http://www.who.int/hiv/pub/surveillance/pub3/en/index.html. Accessed 8
March 2008.
3. Chin J (1990) Public health surveillance of AIDS and HIV infections. Bull
World Health Organ 68: 529–536.
4. UNAIDS, Wellcome Trust Centre for the Epidemiology of Infectious
Diseases (1999) Trends in HIV incidence and prevalence: Natural course of
the epidemic or results of behavioural change? UNAIDS Best Practice
Collection. Geneva: UNAIDS. UNAIDS 99.12e. Available: http://www.who.
int/hiv/strategic/surveillance/pubincprev/en/index.html. Accessed 8 March
2008.
5. Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MPA, et al.
(2006) Declines in HIV prevalence can be associated with changing sexual
behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex
Transm Infect 82: i1–8.
6. Zaba B, Gregson S (1998) Measuring the impact of HIV on fertility in
Africa. AIDS 12: S41–50.
7. Ghys PD, Kufa E, George MVfor the Unaids Reference Group on Estimates
Modelling and Projections’ ad hoc Working Group on interpreting trends
in prevalence and incidence of HIV infection in countries with generalised
epidemics (2006) Measuring trends in prevalence and incidence of HIV
infection in countries with generalised epidemics. Sex Transm Infect 82:
i52–56.
8. [No author listed] (2008) Measure DHS: HIV prevalence. Calverton
(Maryland): Demographic and Health Surveys, Macro International.
Available: http://www.measuredhs.com/topics/hivprev/start.cfm. Accessed 8
March 2008.
9. Boerma JT, Ghys PD, Walker N (2003) Estimates of HIV-1 prevalence from
national population-based surveys as a new gold standard. Lancet 362:
1929–1931.
10. Garcia-Calleja JM, Gouws E, Ghys PD (2006) National population based HIV
prevalence surveys in sub-Saharan Africa: results and implications for HIV
and AIDS estimates. Sex Transm Infect 82: iii64–70.
11. Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, et al.
(2004) The natural history of HIV-1 infection in young Thai men after
seroconversion. J Acquir Immune Deﬁc Syndr 36: 622–629.
12. [No authors listed] (2000) Time from HIV-1 seroconversion to AIDS and
death before widespread use of highly-active antiretroviral therapy: A
collaborative re-analysis. Collaborative Group on AIDS Incubation and
HIV Survival including the CASCADE EU Concerted Action. Concerted
Action on SeroConversion to AIDS and Death in Europe. Lancet 355:
1131–1137.
13. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, et al. (2002) HIV-1
infection in rural Africa: Is there a difference in median time to AIDS and
survival compared with that in industrialized countries? AIDS 16: 597–603.
14. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002)
Quantitative detection of increasing HIV type 1 antibodies after
seroconversion: a simple assay for detecting recent HIV infection and
estimating incidence. AIDS Res Hum Retroviruses 18: 295–307.
15. Karita E, Price M, Hunter E, Chomba E, Allen S, et al. (2007) Investigating
the utility of the HIV-1 BED capture enzyme immunoassay using cross-
sectional and longitudinal seroconverter specimens from Africa. AIDS 21:
403–408.
16. Podgor MJ, Leske MC (1986) Estimating incidence from age-speciﬁc
prevalence for irreversible diseases with differential mortality. Stat Med
5: 573–578.
17. Ades AE, Medley GF (1994) Estimates of disease incidence in women based
on antenatal or neonatal seroprevalence data: HIV in New York City. Stat
Med 13: 1881–1894.
18. Ades AE (1995) Serial HIV seroprevalence surveys: interpretation, design,
and role in HIV/AIDS prediction. J Acquir Immune Deﬁc Syndr Hum
Retrovirol 9: 490–499.
19. Sakarovitch C, Alioum A, Ekouevi DK, Msellati P, Leroy V, et al. (2007)
Estimating incidence of HIV infection in childbearing age African women
using serial prevalence data from antenatal clinics. Stat Med 26: 320–335.
20. Williams B, Gouws E, Wilkinson D, Karim SA (2001) Estimating HIV
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e80 0620
Estimating Incidence from Prevalenceincidence rates from age prevalence data in epidemic situations. Stat Med
20: 2003–2016.
21. White RG, Vynnycky E, Glynn JR, Crampin AC, Jahn A, et al. (2007) HIV
epidemic trend and antiretroviral treatment need in Karonga District,
Malawi. Epidemiol Infect: 1–11.
22. Gregson S, Donnelly CA, Parker CG, Anderson RM (1996) Demographic
approaches to the estimation of incidence of HIV-1 infection among adults
from age-speciﬁc prevalence data in stable endemic conditions. AIDS 10:
1689–1697.
23. Saidel T, Sokal D, Rice J, Buzingo T, Hassig S (1996) Validation of a method
to estimate age-speciﬁc human immunodeﬁciency virus (HIV) incidence
rates in developing countries using population-based seroprevalence data.
Am J Epidemiol 144: 214–223.
24. Batter V, Matela B, Nsuami M, Manzila T, Kamenga M, et al. (1994) High
HIV-1 incidence in young women masked by stable overall seroprevalence
among childbearing women in Kinshasa, Zaire: estimating incidence from
serial seroprevalence data. AIDS 8: 811–817.
25. UNAIDS Reference Group on Estimates Modelling and Projections (2002)
Improved methods and assumptions for estimation of the HIV/AIDS
epidemic and its impact: Recommendations of the UNAIDS Reference
Group on Estimates, Modelling and Projections. AIDS 16: W1–14.
26. Zaba B, Marston M, Crampin M, Isingo R, Biraro S, et al. (2007) Age-speciﬁc
mortality patterns of HIV infected persons: a comparative analysis of
community study data from ﬁve African countries. AIDS 21: S87–S96.
27. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, et al. (2007) Time from
HIV seroconversion to death: A collaborative analysis of eight studies in six
low and middle-income countries before highly active antiretroviral
therapy. AIDS 21: S55–S63.
28. UNAIDS/WHO (2007) AIDS epidemic update. Geneva: UNAIDS. Available:
http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/
EpiUpdArchive/2007/default.asp. Accessed 8 March 2008.
29. Gregson S, Garnett GP, Nyamukapa CA, Hallett TB, Lewis JJ, et al. (2006)
HIV decline associated with behavior change in eastern Zimbabwe. Science
311: 664–666.
30. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kengeya-Kayondo JF (1994)
HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan
population cohort. AIDS 8: 87–92.
31. Boerma JT, Urassa M, Senkoro K, Klokke A, Ngweshemi JZ (1999) Spread of
HIV infection in a rural area of Tanzania. AIDS 13: 1233–1240.
32. Lopman B, Nyamukapa C, Mushati P, Mupambireyi Z, Mason P, et al. (2008)
HIV incidence in 3 years of follow-up of a Zimbabwe cohort—1998–2000 to
2001–03: contributions of proximate and underlying determinants to
transmission. Int J Epidemiol 37: 88–105.
33. Wambura M, Urassa M, Isingo R, Ndege M, Marston M, et al. (2007) HIV
prevalence and incidence in rural Tanzania: results from 10 years of follow-
up in an open-cohort study. J Acquir Immune Deﬁc Syndr 46: 616–623.
34. Shafer LA, Biraro S, Kamali A, Grosskurth H, Kirungi W, et al. (2006) HIV
prevalence and incidence are no longer falling in Uganda—a case for
renewed prevention efforts: evidence from a rural population cohort 1989–
2005, and from ANC surveillance [Abstract THLB0108]. 16th International
AIDS Conference. 2006 August; Toronto, Canada. International AIDS
Society. Available: http://www.iasociety.org/Search.aspx. Accessed 8 March
2008.
35. Kamali A, Carpenter LM, Whitworth JA, Pool R, Ruberantwari A, et al.
(2000) Seven-year trends in HIV-1 infection rates, and changes in sexual
behaviour, among adults in rural Uganda. AIDS 14: 427–434.
36. Boerma JT, Stanecki KA, Newell ML, Luo C, Beusenberg M, et al. (2006)
Monitoring the scale-up of antiretroviral therapy programmes: Methods to
estimate coverage. Bull World Health Organ 84: 145–150.
37. Garnett GP, Garcia-Calleja JM, Rehle T, Gregson S (2006) Behavioural data
as an adjunct to HIV surveillance data. Sex Transm Infect 82: i57–62.
38. Hallett TB, White PJ, Garnett GP (2007) Appropriate evaluation of HIV
prevention interventions: From experiment to full-scale implementation.
Sex Transm Infect 83: i55–60.
39. Porter K, Zaba B (2004) The empirical evidence for the impact of HIV on
adult mortality in the developing world: data from serological studies. AIDS
18: S9–S17.
40. Duckett M (2000) Migrants and HIV / AIDS. Dev Bull: 18–20.
41. UNAIDS, International Organisation for Migration (2001) Population
mobility and AIDS: UNAIDS technical update. Geneva: UNAIDS. Available:
http://data.unaids.org/Publications/IRC-pub02/JC513-PopMob-TU_en.pdf.
Accessed 8 March 2008.
42. International Organisation for Migration (2004) Population mobility and
HIV/AIDS. Available: http://www.old.iom.int/documents/publication/en/
iom_hiv_brochure_july_2004.pdf. Accessed 8 March 2008.
43. Mundandi C, Vissers D, Voeten H, Habbema D, Gregson S (2006) No
difference in HIV incidence and sexual behaviour between out-migrants
and residents in rural Manicaland, Zimbabwe. Trop Med Int Health 11:
705–711.
44. World Health Organization, UNAIDS, UNICEF (2007) Towards universal
access: Scaling up priority HIV/AIDS interventions in the health sector.
Available: http://www.who.int/hiv/mediacentre/. Accessed 30 October 07.
PLoS Medicine | www.plosmedicine.org April 2008 | Volume 5 | Issue 4 | e80 0621
Estimating Incidence from PrevalenceEditors’ Summary
Background. More than 25 million people have died from AIDS and
about 33 million people are currently infected with human immunode-
ficiency virus (HIV, the virus that causes AIDS). Faced with this threat to
human health, governments and international agencies are working
together to halt the AIDS epidemic. An important part of this effort is HIV
surveillance. The spread of HIV needs to be monitored to assess the
impact of interventions (for example, the provision of antiretroviral
drugs) and to plan for current and future health care needs. HIV
surveillance in countries where the epidemic has spread beyond specific
groups into the whole population (a generalized epidemic) has mainly
relied on determining the prevalence of HIV infection (the fraction of the
population that is infected) among women attending antenatal clinics.
Recently, however, household health surveys (for example, the
Demographic and Health Surveys) have begun to use blood testing for
antibodies to the AIDS virus (serological testing) to provide more
accurate estimates of HIV prevalence in the general adult population.
Why Was This Study Done? Although prevalence estimates provide
useful information about the HIV epidemic, another important indicator
is incidence—the number of new infections occurring during a specific
time period. Incidence measurements provide more information about
temporal changes in the epidemic and transmission patterns and allow
public-health experts to make better predictions of future health care
needs. But, whereas prevalence can be measured with anonymized
serological surveys, individuals would have to be identified and followed
up in repeat serological surveys to provide a direct measurement of
incidence. This is expensive and hard to achieve in many settings. In this
study, therefore, the researchers develop and validate two mathematical
methods to estimate HIV incidence in generalized HIV epidemics from
prevalence data.
What Did the Researchers Do and Find? Changes in the fraction of the
population living with HIV (prevalence) can occur not only because of
changes in the rate of new infections (incidence), but also because
mortality rates are much higher for infected individuals than others. The
researchers’ methods disentangle the contributions to HIV prevalence (as
measured in serological surveys) made by new infections from those due
to deaths from AIDS and other causes. Their first method incorporates
information on death rates collected in cohort studies of HIV infection
(cohort studies investigate outcomes in groups of people); their second
method uses information on survival after HIV infection, also collected in
long-running cohort studies. The accuracy of both methods was
assessed using computer-simulated data and actual data on HIV
prevalence and incidence collected in three community-based cohort
studies in Zimbabwe and Uganda (countries with generalized but
declining HIV epidemics) and Tanzania (a country with a generalized,
stable epidemic). Both methods provided accurate estimates of HIV
incidence from the simulated data. Using the data collected in Africa, the
mean difference between actual measurements of incidence and the
estimate provided by method 1 was 19%; for method 2 it was 14%. In
addition, the measured and estimated incidences were in good
agreement for all age groups.
What Do These Findings Mean? These findings suggest HIV incidence
rates can be estimated from repeat surveys of prevalence with sufficient
accuracy to monitor the HIV epidemic. The accuracy of the estimates
across all age groups is particularly important because knowledge of the
age-related risk pattern provides the information on transmission
patterns that is needed to design effective intervention programs.
Because these methods were tested using data only from southern and
eastern Africa where the HIV epidemic is mature and generalized, they
may not work as well in regions where the epidemic is restricted to
subsets of the population. Other factors that might affect their accuracy
include the amount of international migration and the uptake of
antiretroviral therapies. Nevertheless, with the increased availability of
serial measurements of serological prevalence, these new methods for
estimating HIV incidence from HIV prevalence could prove extremely
useful for monitoring the progress of national HIV epidemics and for
guiding HIV control programs. The authors include spreadsheets that can
be used to calculate incidence by either method from consecutive survey
data.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050080.
  The US National Institute of Allergy and Infectious Diseases provides
information on HIV infection and AIDS
  The US Centers for Disease Control and Prevention provides
information on global HIV/AIDS topics (in English and Spanish)
  The HIV InSite provides comprehensive and up-to-date information on
all aspects of HIV/AIDS from the University of California San Francisco,
including country reports on the AIDS epidemic in 195 countries,
including Uganda, Zimbabwe, and Tanzania
  Avert, an international AIDS charity, provides information on all
aspects of HIV/AIDS, including fact sheets on understanding HIV and
AIDS statistics, and on HIV and AIDS in Africa
  The Demographic and Health Surveys program collects, analyzes, and
disseminates information on health and population trends in countries
around the world
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